![R. Jacob Vogelstein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
R. Jacob Vogelstein
Fondateur chez
Mind-X Corp.
Profil
Dr. Rachel J.
Vogelstein is a Co-Founder & Managing Partner at Catalio Capital Management LP, a Chief Executive Officer at Cage Pharma, Inc., an Advisor at Mind-X Corp.
and a Director & Manager at Catalio Genesis Fund II LLC.
He is on the Board of Directors at Catalio Access Fund V LLC, Catalio Genesis Fund IV LLC, Catalio Special Opportunities Fund III LLC, Haystack Oncology, Inc., Iambic Therapeutics, Inc. and Catalio Genesis Fund II LLC.
He is primarily responsible for managing the firm and for making investments in private breakthrough biomedical technology companies.
He serves on the Investment Committee of Catalio’s flagship Nexus strategy and on the firmwide Management Committee.
Dr. Vogelstein was previously employed as a Partner by Camden Partners Private Equity and Global Domain Partners LLC, and an Advisor by Gigantum, Inc. He also served on the board at Aruene Corp.
and Metabolon, Inc.
He earned his BSc.
degree in Bio-Electrical Engineering from Brown University and his Ph.D.
degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.
Postes actifs de R. Jacob Vogelstein
| Sociétés | Poste | Début |
|---|---|---|
Mind-X Corp.
 Mind-X Corp. Packaged SoftwareTechnology Services Develops software applications | Fondateur | 01/01/2017 |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Fondateur | 01/06/2020 |
Catalio Access Fund V LLC
 Catalio Access Fund V LLC Investment ManagersFinance Functions as a venture capital fund | Directeur/Membre du Conseil | - |
Cage Pharma, Inc.
 Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical drugs | Directeur Général | 01/12/2017 |
Catalio Special Opportunities Fund Iii LLC
 Catalio Special Opportunities Fund Iii LLC Investment ManagersFinance Functions as a venture capital fund | Directeur/Membre du Conseil | - |
Catalio Genesis Fund II LLC
 Catalio Genesis Fund II LLC Investment ManagersFinance Functions as a venture capital fund | Directeur/Membre du Conseil | - |
Catalio Genesis Fund IV LLC
 Catalio Genesis Fund IV LLC Investment ManagersFinance Functions as a venture capital fund | Directeur/Membre du Conseil | - |
Catalio Capital Management LP (Investment Management)
 Catalio Capital Management LP (Investment Management) Investment ManagersFinance Catalio-IM aims to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management and execution. The firm’s public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy that invests in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data. The strategy’s investment style is a “best idea” orientation focused on identifying mis-priced risk in clinical, regulatory, intellectual property, manufacturing, commercial, and management. | Directeur Général | 01/01/2020 |
Haystack Oncology, Inc.
 Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Operates as an oncology care and MRD testing center | Directeur/Membre du Conseil | - |
| ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de R. Jacob Vogelstein
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
| ░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de R. Jacob Vogelstein
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
7
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
Metabolon, Inc.
 Metabolon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides metabolomics analysis and bioinformatics solutions using software | Commercial Services |
Global Domain Partners LLC
 Global Domain Partners LLC Investment Banks/BrokersFinance Provides security and trading services | Finance |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Camden Partners Private Equity
 Camden Partners Private Equity Investment ManagersFinance Camden Partners invests in lower middle market companies located in the United States with an enterprise value ranging from USD 10 to 150 million and revenues of USD 10 to 50 million. The firm target companies operating in the fields of technology, software, business services and education sectors and industries. It provides financing for buyout and growth stage transactions with an investment size ranging from USD 5 to 15 million. | Finance |
Aruene Corp.
 Aruene Corp. Medical SpecialtiesHealth Technology Develops portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for treatment of migraine | Health Technology |
Cage Pharma, Inc.
Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical drugs | Health Technology |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mind-X Corp.
Mind-X Corp. Packaged SoftwareTechnology Services Develops software applications | Technology Services |
Gigantum, Inc.
 Gigantum, Inc. Packaged SoftwareTechnology Services Develops open-source platform | Technology Services |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Finance |
Entos, Inc.
 Entos, Inc. Packaged SoftwareTechnology Services Develops AI driven platform for drug discovery | Technology Services |
Catalio Access Fund V LLC
Catalio Access Fund V LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Genesis Fund II LLC
Catalio Genesis Fund II LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Genesis Fund IV LLC
Catalio Genesis Fund IV LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Special Opportunities Fund Iii LLC
Catalio Special Opportunities Fund Iii LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Operates as an oncology care and MRD testing center | Health Services |
Catalio Capital Management LP (Investment Management)
Catalio Capital Management LP (Investment Management) Investment ManagersFinance Catalio-IM aims to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management and execution. The firm’s public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy that invests in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data. The strategy’s investment style is a “best idea” orientation focused on identifying mis-priced risk in clinical, regulatory, intellectual property, manufacturing, commercial, and management. | Finance |
